CONCORD, Calif. -- Cerus Corporation (Nasdaq:CERS) announced today that Company management will present at the Robert W. Baird & Co.'s 2006 Focus on Oncology Conference. Cerus' presentation will begin at 11:05 a.m. EDT on Wednesday, August 2, 2006. To access the live webcast, please log on to the Company's website at www.cerus.com. An archived presentation will be available on the website until August 16, 2006.

ABOUT CERUS

Cerus Corporation is developing and commercializing novel, proprietary products and technologies within the fields of immunotherapy and blood safety that are intended to provide safer, more effective medical options to patients in areas of substantial unmet medical needs. In the field of immunotherapy, the company is employing its proprietary attenuated Listeria vaccine platform to develop a series of novel therapies to treat cancer, and it is applying its proprietary Killed But Metabolically Active technology platform in research and development of prophylactic and therapeutic vaccines for infectious diseases. In the field of blood safety, the company is developing and commercializing the INTERCEPT Blood System, which is based on the company's proprietary Helinx technology and is designed to enhance the safety of donated blood components by inactivating viruses, bacteria, parasites and other pathogens, as well as potentially harmful white blood cells.

INTERCEPT, INTERCEPT Blood System and Helinx are trademarks of Cerus Corporation.